A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Linking genetic data with electronic health records in hospital biobanks promises to advance precision medicine, but limited ancestral diversity constrains discovery and generalizability. We analyzed 93,936 participants from the UCLA ATLAS Community…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed metabolic and aesthetic medicine, yet their potential influence on botulinum toxin type A (BoNT-A) pharmacodynamics remains unexplored. Using the AesthetiSIM™ microsimulation plat…
Whether the risk of gastric neoplasm is modified by newer glucose-lowering therapies-dipeptidyl peptidase-4 inhibitors (DPP4is), glucagon-like peptide-1 receptor agonists (GLP1RAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2is)-remains unce…
Incretin therapies have emerged as key interventions for glycemic control and weight reduction and are now among Canada's costliest outpatient drug classes. This review synthesizes current clinical and economic evidence on the cost-effectiveness of i…
AIMS: Oral semaglutide absorption is subject to inter-individual variability. We investigated whether estimated individual exposure (eC) provides predictive information beyond the prescribed dose in a real-world cohort of patients with type 2 diabete…
BACKGROUND: Coronary microembolization (CME) is the major leading cause of perioperative myocardial injury during coronary revascularization. Semaglutide exerts multiple protective biological activities, but its cardioprotective effects on CME remain…
INTRODUCTION: Familial partial lipodystrophy type 2 (FPLD2) is a rare autosomal dominant laminopathy caused by LMNA gene variants. It is characterized by progressive gluteofemoral lipoatrophy and severe metabolic derangements, including insulin resis…
OBJECTIVES: This study aimed to identify key regulatory genes involved in chondrocyte senescence in osteoarthritis (OA) and to evaluate the therapeutic potential of the GLP-1 receptor agonist semaglutide. METHODS: Transcriptomic data of chondrocytes…
Euthyroid sick syndrome (ESS) is characterized by abnormal thyroid function tests, most notably a low triiodothyronine (T3) level, occurring in the absence of intrinsic thyroid disease. A 54-year-old woman presented to the endocrinology clinic with a…
AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for metabolic disorders, but emerging safety concerns include alopecia and reproductive or endocrine-related adverse events (AEs). This study investigated the association bet…
Obesity, a global public health crisis driven by complex interactions of genetic, environmental, and behavioral factors, necessitates innovative therapeutic strategies. This review explores the pathogenesis of obesity, emphasizing genetic determinant…
BACKGROUND: Prediabetes refers to the transitional stage from normal glucose metabolism to diabetes. The International Diabetes Federation guidelines reported that, as of 2024, approximately 1.12 billion people globally were in the prediabetes stage.…
OBJECTIVES: To investigate the clinical characteristics of weight loss drugs (WLDs) users in Norway. DESIGN: Nested population-based case-control study. SETTING: Nationwide healthcare registries with data on dispensed medications and healthcare diagn…
Metabolic disorders have been recognized as a major contributor to the occurrence and progression of osteoarthritis (OA). Identifying novel therapeutic agents to ameliorate the progression of OA with metabolic disorder is crucial. In this study, we d…
OBJECTIVE: Semaglutide improves cardiovascular disease (CVD) risk in people who are diabetic, overweight or obese through incompletely understood mechanisms. To address this, we explored novel lipidomic and lipo-/glyco-protein profiling with semaglut…
Marine macroalgae are increasingly recognized as sources of bioactive compounds with potential benefits for metabolic health. This study investigated the chemical composition and metabolic effects of a 70% ethanol extract of the edible red algain a h…
BACKGROUND: Peripheral artery disease (PAD) is a prevalent and debilitating complication of diabetes and obesity, yet it remains underrecognized and undertreated. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, have shown…
AIMS: To examine the impact of FDA approval of semaglutide (Wegovy) for chronic weight management on the utilization gap between males and females in the United States. MATERIALS AND METHODS: The study utilized 2019-2024 MarketScan commercial claims…
OBJECTIVE: This study aimed to assess weight and safety outcomes in a large national cohort of patients with overweight and obesity treated with GLP-1 medications via telehealth. METHODS: Data were obtained from deidentified EHRs for a random sample…
Obesity is a complex metabolic disorder associated with an increased risk of type 2 diabetes, cardiovascular diseases, and metabolic dysfunction-associated steatotic liver disease. While protein-based therapies like glucagon-like peptide-1 (GLP-1) re…